Effect of eszopiclone on sleep, fatigue, and pain in patients with mucositis associated with hematologic malignancies

Joel E Dimsdale, Edward D Ball, Ewa Carrier, Mark Wallace, Peter Holman, Carolyn Mulroney, Farah Shaikh, Loki Natarajan, Joel E Dimsdale, Edward D Ball, Ewa Carrier, Mark Wallace, Peter Holman, Carolyn Mulroney, Farah Shaikh, Loki Natarajan

Abstract

Purpose: Patients with malignancy sometimes develop painful mucositis and require patient-controlled analgesia (PCA) to treat their pain. Pain disrupts sleep and there is some evidence that analgesic medications also disrupt sleep. This study examined whether treatment with the sedative hypnotic eszopiclone could improve self-reports of sleep, fatigue, and pain as well as decrease opioid self-administered via PCA.

Methods: Inpatients who developed mucositis severe enough to require PCA treatment were randomized double-blind to a 2-day trial on eszopiclone or placebo-administered at bedtime. Patients completed questionnaires which assessed sleep, pain, and fatigue. PCA medication was calculated in terms of morphine equivalents. Data were analyzed with unpaired t tests and repeated measures analysis of variance.

Results: Twenty-two patients were randomized to placebo and 23 to eszopiclone. Groups were comparable in age and treatment characteristics. Mean pain scores were lower in the eszopiclone group at all time points (morning p = 0.01, afternoon p = 0.04, evening p = 0.04). The eszopiclone group reported increased sleep time (p < 0.05), fewer nighttime awakenings (p < 0.001), better self-reported sleep quality (p = 0.01), and depth (p = 0.04). There were no significant differences between eszopiclone and placebo in terms of self-reports of fatigue or opioid usage.

Conclusion: Sedative hypnotic agents improve sleep and analgesia even in the setting of considerable pain and discomfort.

Figures

Fig. 1
Fig. 1
Patient flow diagram
Fig. 2
Fig. 2
Sleep effects
Fig. 3
Fig. 3
Effects of eszopiclone on pain. Mean ± SEM pain score by time of day and treatment arm; pain score for each patient at each time point is the average score across 2 days

References

    1. Moore P, Dimsdale J. Opioids, sleep, and cancer-related fatigue. Med Hypotheses. 2002;58:77–82. doi: 10.1054/mehy.2001.1461.
    1. Dimsdale J, Norman D, Dejardin D, Wallace M. The effects of opioids on sleep architecture. J Clin Sleep Med. 2007;15:33–36.
    1. Roehrs T, Hyde M, Blaisdell B, Greenwald M, Roth T. Sleep loss and REM sleep loss are hyperalgesic. Sleep. 2006;29:137–139.
    1. Moore J, Kelz M. Opiates, sleep, and pain: the adenosinergic link. Anesthesiology. 2009;111:1175–1176. doi: 10.1097/ALN.0b013e3181bdfa2e.
    1. Raymond I, Nielsen TA, Lavigne G, Manzini C, Choiniere M. Quality of sleep and its daily relationship to pain intensity in hospitalized adult burn patients. Pain. 2001;92:381–388. doi: 10.1016/S0304-3959(01)00282-2.
    1. Affleck G, Urrows S, Tennen H, Higgins P, Abeles M. Sequential daily relations of sleep, pain intensity, and attention to pain among fibromyalgia patients. Pain. 1996;68:363–368. doi: 10.1016/S0304-3959(96)03226-5.
    1. Haack M, Sanchez E, Mullington J. Elevated inflammatory markers in response to prolonged sleep restriction are associated with increased pain experience in healthy volunteers. Sleep. 2007;30(9):1145–1152.
    1. Kundermann B, Krieg J, Schreiber W, Lautenbacher S. The effect of sleep deprivation on pain. Pain Res Manag. 2004;9:25–32.
    1. Moldofsky H, Scarisbrick P. Induction of neurasthenic musculoskeletal pain syndrome by selective sleep stage deprivation. Psychosom Med. 1976;38:35–44.
    1. Onen S, Alloui A, Gross A, Eschallier A, Dubray C. The effects of sleep deprivation, selective sleep interruption and sleep recovery on pain tolerance thresholds in healthy subjects. J Sleep Res. 2001;10:35–42. doi: 10.1046/j.1365-2869.2001.00240.x.
    1. Strobel ES, Bauchmuller K, Ihorst G, Engelhardt M. Frequency, severity and risk factors for oral mucositis after BEAM conditioning and autologous peripheral blood stem cell transplantation: a single center analysis and review of the literature. Leuk Lymphoma. 2007;48:2255–2260. doi: 10.1080/10428190701636492.
    1. Bensinger W, Schubert M, Ang KK, Brizel D, Brown E, Eilers JG, Elting L, Mittal BB, Schattner MA, Spielberger R, Treister NS, Trotti AM., 3rd NCCN Task Force report: prevention and management of mucositis in cancer care. J Natl Compr Canc Netw. 2008;6(Suppl 1):S1–S21.
    1. Niscola P, Romani C, Cupelli L, Scaramucci L, Tendas A, Dentamaro T, Amadori S, de Fabritiis P. Mucositis in patients with hematologic malignancies: an overview. Haematologica. 2007;92(2):222–231. doi: 10.3324/haematol.10232.
    1. Roth T, Price JM, Amato DA, Rubens RP, Roach JM, Schnitzer TJ. The effect of eszopiclone in patients with insomnia and coexisting rheumatoid arthritis. Prim Care Companion J Clin Psychiatry. 2009;11(6):292–301. doi: 10.4088/PCC.08m00749bro.
    1. McNair D, Lorr M, Droppleman L. Manual for the profile of mood states. San Diego: Educational and Industrial Testing Service; 1971.
    1. Ancoli-Israel S, Krystal AD, McCall WV, Schaefer K, Wilson A, Claus R, Rubens R, Roth T. A 12-week, randomized, double-blind, placebo-controlled study evaluating the effect of eszopiclone 2 mg on sleep/wake function in older adults with primary and comorbid insomnia. Sleep. 2010;33:225–234.
    1. Bailes S, Libman E, Baltzan M, Amsel R, Schondorf R, Fichten C. Brief and distinct empirical sleepiness and fatigue scales. J Psychosom Res. 2006;60:605–613. doi: 10.1016/j.jpsychores.2005.08.015.
    1. Portenoy R. Clinical application of opioid analgesics. In: Sinatra RS, Hord AH, Ginsberg B, Preble LM, editors. Acute pain: mechanisms and management. St. Louis: Mosby Year Book; 1992. pp. 93–101.

Source: PubMed

Sponsorzy i współpracownicy

Warunki medyczne

Interwencje lekowe

3
Subskrybuj